TrialDiabetes, obesity & metabolism2017

A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes.

Ira Gantz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.